Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs CS-3006 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors CStone Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2018 New trial record
    • 29 Oct 2018 According to a CStone Pharmaceuticals media release, this trial will led by Dr. Xu Jianming of the 307th Hospital of the Chinese People's Liberation Army.
    • 29 Oct 2018 According to a CStone Pharmaceuticals media release, first patient has been successfully enrolled and dosed at the 307th Hospital of the Chinese People's Liberation Army in Beijing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top